Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index

Here's a roundup of top developments in the biotech space since Tuesday morning.

Scaling the Peaks

(Stocks hitting 52-week highs on July 3)

  • Arbutus Biopharma Corp ABUS
  • Arrowhead Pharmaceuticals Inc ARWR
  • BioLife Solutions Inc BLFS
  • Merus NV MRUS
  • Regenxbio Inc RGNX
  • SurModics, Inc. SRDX
  • Veracyte Inc VCYT
  • Zafgen Inc ZFGN

Down In The Dumps

(Stocks hitting 52-week lows on July 3)

  • Autolus Therapeutics Ltd – ADR AUTL
  • Curis, Inc. CRIS
  • Erytech Pharma SA (ADR) ERYP
  • Neos Therapeutics Inc NEOS
  • Opiant Pharmaceuticals Inc OPNT
  • TrovaGene Inc TROV
  • ZEALAND PHARMA/S ADR ZEAL

Related Link: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Stocks In Focus

Realm ADS to Begin Trading On Nasdaq

Realm Therapeutics PLC RLM, which develops therapies for immune-related diseases, said the SEC has declared effective registration statements on Form F-1 and F-6 with respect to the ADSs, representing its ordinary shares, that are to be listed on the Nasdaq.

The company said the ADSs will begin trading on the Nasdaq under the ticker symbol RLM on Thursday.

Currently, shares of the company are listed on the AIM, a U.K. exchange for small and growing companies.

CASI Added to the Russell 2000 Index

CASI Pharmaceuticals Inc CASI said its stock has been added to the Russell 2000, 3000 as well as the Microcap Indexes, effective after the close of market on June 22.

Posted In: BiotechNewsTop StoriesPre-Market OutlookTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...